Correlation Between Sarana Meditama and Diagnos Laboratorium

Can any of the company-specific risk be diversified away by investing in both Sarana Meditama and Diagnos Laboratorium at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sarana Meditama and Diagnos Laboratorium into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Sarana Meditama Metropolitan and Diagnos Laboratorium Utama, you can compare the effects of market volatilities on Sarana Meditama and Diagnos Laboratorium and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sarana Meditama with a short position of Diagnos Laboratorium. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sarana Meditama and Diagnos Laboratorium.

Diversification Opportunities for Sarana Meditama and Diagnos Laboratorium

0.57

Correlation Coefficient

Sarana Meditama  Diagnos Laboratorium

Very weak diversification

The 3 months correlation between Sarana and Diagnos is 0.57. Overlapping area represents the amount of risk that can be diversified away by holding Sarana Meditama Metropolitan and Diagnos Laboratorium Utama in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Diagnos Laboratorium and Sarana Meditama is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sarana Meditama Metropolitan are associated (or correlated) with Diagnos Laboratorium. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Diagnos Laboratorium has no effect on the direction of Sarana Meditama i.e., Sarana Meditama and Diagnos Laboratorium go up and down completely randomly.

Pair Corralation between Sarana Meditama and Diagnos Laboratorium

Assuming the 90 days trading horizon Sarana Meditama is expected to generate 1.58 times less return on investment than Diagnos Laboratorium. But when comparing it to its historical volatility, Sarana Meditama Metropolitan is 1.16 times less risky than Diagnos Laboratorium. It trades about 0.01 of its potential returns per unit of risk. Diagnos Laboratorium Utama is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  24,800  in Diagnos Laboratorium Utama on September 4, 2024 and sell it today you would lose (2,200) from holding Diagnos Laboratorium Utama or give up 8.87% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	99.79%
Values	Daily Returns

Sarana Meditama Metropolitan  vs.  Diagnos Laboratorium Utama

Sarana Meditama Metr

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Sarana Meditama Metropolitan has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent forward-looking signals, Sarana Meditama is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors.

Diagnos Laboratorium

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Diagnos Laboratorium Utama has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's forward-looking signals remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with Sarana Meditama and Diagnos Laboratorium

The main advantage of trading using opposite Sarana Meditama and Diagnos Laboratorium positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sarana Meditama position performs unexpectedly, Diagnos Laboratorium can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Diagnos Laboratorium will offset losses from the drop in Diagnos Laboratorium's long position.

The idea behind Sarana Meditama Metropolitan and Diagnos Laboratorium Utama pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.